Stephen Gardell, Ph.D.

Stephen Gardell's Research Focus

Cardiovascular Diseases, Atherosclerosis, Heart Disease, Type 2 Diabetes, Cardiomyopathies

Dr. Stephen Gardell aims to use his 20 years of experience in the pharmaceutical industry to drive the advancement of basic research discoveries to realize their potential therapeutic utility. In particular, he oversees the development and operation of several advanced technology core facilities: Metabolomics, Cardiometabolic Phenotyping, Histopathology, Cellular Imaging and the Vivarium at Lake Nona. His personal laboratory pursuits are centered around the role of LXR, a nuclear hormone receptor, and its endogenous oxysterol ligands in cardiovascular disease.

Stephen Gardell's Research Report

LXR agonists are known to exert remarkable efficacy in murine models of atherosclerosis. The current dogma is that efficacy arises from stimulation of reverse cholesterol transport whereby cholesterol is exported from the vessel wall (accumulated in “foam cells”) and transferred back to the liver where it is eliminated. This is probably not the whole story. The experiments in my laboratory are aimed at achieving a deeper understanding about the LXR-regulated mechanisms that operate at/in the vessel wall that serve to impede the development of atherosclerotic lesions.

Stephen Gardell's Bio

Stephen Gardell, Ph.D., received a B.S. degree in Biology from Boston College and a Ph.D. degree in Biochemistry from the Cornell University Graduate School of Medical Sciences. He performed postdoctoral studies at the University of California, San Francisco (UCSF) in the laboratory of Dr. William J. Rutter. Dr. Gardell joined Merck Research Laboratories (West Point, PA) in 1987, where he studied thrombosis and Alzheimer’s disease. His investigations of the secretases provided key insight into the pathophysiology of Alzheimer’s disease. In 2001, Dr. Gardell became the Director of Obesity Research at Bayer Research (West Haven, CT), where he pursued weight loss strategies involving appetite control and energy expenditure. In 2004, Dr. Gardell became Assistant Vice President, Cardiovascular Discovery Research at Wyeth where he directed programs in atherosclerosis, heart failure, thrombosis and arrhythmias. Dr. Gardell originally joined SBP in 2009.

Cardiovascular Metabolism Accessory


Aubert G, Martin OJ, Horton JL, Lai L, Vega RB, Leone TC, Koves T, Gardell SJ, Krüger M, Hoppel CL, Lewandowski ED, Crawford PA, Muoio DM, Kelly DP
Circulation 2016 Feb 23;133(8):698-705
He Q, Wang M, Petucci C, Gardell SJ, Han X
Int J Biochem Cell Biol 2013 Dec;45(12):2749-55
Brouwers B, Stephens NA, Costford SR, Hopf ME, Ayala JE, Yi F, Xie H, Li JL, Gardell SJ, Sparks LM, Smith SR
Front Physiol 2018;9:704
Zhang X, Trevino MB, Wang M, Gardell SJ, Ayala JE, Han X, Kelly DP, Goodpaster BH, Vega RB, Coen PM
J Gerontol A Biol Sci Med Sci 2018 Sep 11;73(10):1313-1322
Costford SR, Brouwers B, Hopf ME, Sparks LM, Dispagna M, Gomes AP, Cornnell HH, Petucci C, Phelan P, Xie H, Yi F, Walter GA, Osborne TF, Sinclair DA, Mynatt RL, Ayala JE, Gardell SJ, Smith SR
Mol Metab 2018 Jan;7:1-11